Final Patient Enrolled in Landmark Alzheimer’s Treatment Trial Targeting Stress Hormone Cortisol
November 25 2018 - 5:44PM
Business Wire
- Significant milestone achieved for
XanADu, with final patient enrolled into trial
- A total of 186 patients have been
enrolled into XanADu, surpassing initial target of 174
- Final patient will complete trial in 4
months (3 months on treatment with a follow-up 1 month after
treatment)
- Completion of study, and announcement
of results on track for 2Q CY19
Actinogen Medical ASX: ACW (‘ACW’ or ‘the Company’) is
pleased to announce it has enrolled the final patient into XanADu,
its Phase II clinical trial of Xanamem in the treatment of patients
with mild Alzheimer’s disease.
A total of 186 patients have been enrolled into the study,
surpassing the Company’s initial target of 174 patients. The
increased enrolment numbers followed high engagement from study
sites and research teams participating in this important global
Alzheimer’s trial.
XanADu is a randomized, double-blind, multi-centre clinical
study comparing Xanamem to placebo in patients with mild dementia
due to Alzheimer’s disease. XanADu is the largest and most
comprehensive international Alzheimer’s treatment trial run by an
Australian biotech company.
The final patient will complete the trial in four months,
following three months of treatment with Xanamem or placebo
followed by a one-month observation period off-treatment. All the
trial data will then be collated, reviewed, and quality controlled,
before being analysed. The Company is on track to report out the
results during the second quarter 2019, as previously
announced.
CEO of Actinogen Medical, Dr Bill Ketelbey commented: “Enrolment
of the final patient into XanADu represents a major milestone for
Actinogen, as we now have certainty on the timeline to completion
of the trial and to the reporting out of the results. We eagerly
await the trial outcomes as they may be a significant
step forward in developing an effective new treatment approach for
patients with mild Alzheimer’s disease, and could make a
substantial impact in the future treatment of this devastating
disease.”
“I’d like to thank all patients who participated in this trial,
their families and carers, and all the trial sites around the
world. Their commitment to medical research, and to extending our
understanding of cognitive impairment and Alzheimer’s disease,
benefits society as a whole and could help uncover important new
drugs to treat these diseases.”
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181125005155/en/
Actinogen MedicalDr. Bill KetelbeyCEO & Managing
DirectorP: +61 2 8964 7401E:
bill.ketelbey@actinogen.com.au@BillKetelbey
Investor and Media EnquiriesBen WalshWE BuchanM:
+61 411 520 012E: bwalsh@we-buchan.com
Actinogen Medical (ASX:ACW)
Historical Stock Chart
From Nov 2024 to Dec 2024
Actinogen Medical (ASX:ACW)
Historical Stock Chart
From Dec 2023 to Dec 2024